Strides Pharma Science Limited has released the audio recording of its earnings call discussing the unaudited financial results for the quarter ended June 30, 2026. The call took place on Friday, July 31, 2026, at 17:00 hrs IST, providing investors and analysts with management commentary on the company's latest performance metrics. This disclosure ensures transparency and accessibility for stakeholders reviewing the Q4FY26 outcomes.

The release was made pursuant to Regulations 30 and 46 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. These regulations mandate timely dissemination of material information to listed entities' shareholders and the broader market. By hosting the audio on its official website, Strides Pharma Science Limited complies with regulatory requirements for investor communication.

Earnings Call Details

The earnings call was conducted by Strides Pharma Science Limited to review its financial standing for the most recent quarter. The session allowed for direct interaction between company leadership and market participants, addressing queries related to operational performance and strategic initiatives.

Regulatory Compliance

Manjula Ramamurthy, Company Secretary & Compliance Officer at Strides Pharma Science Limited, signed off on the disclosure. Her ICSI Membership No. A30515 is cited in the official communication submitted to both the Bombay Stock Exchange (BSE) and the National Stock Exchange of India Limited (NSE). The notice was directed to the respective exchange offices in Mumbai.

The audio recording is accessible via the company’s investor relations portal. Stakeholders are advised to refer to the specific URL provided in the original filing for immediate access to the recording. This mechanism supports efficient information flow without requiring physical attendance or additional distribution channels.

Strides Pharma Science reported a 16% year-on-year increase in standalone net profit for the quarter ended June 30, 2026, reaching ₹2,113.26 lakh. The pharmaceutical company’s total income from operations rose to ₹20,870.93 lakh from ₹19,664.02 lakh in the same period last year, demonstrating resilient top-line growth amid market fluctuations.

The Board of Directors approved the unaudited financial results on July 31, 2026, following a review by the Audit Committee. The statutory auditors carried out a limited review of the accounts. These results were filed with the National Stock Exchange of India Limited and BSE Limited pursuant to Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Financial Performance

Standalone profit before tax increased to ₹2,814.42 lakh from ₹2,386.18 lakh in Q1FY25. Consolidated net profit stood at ₹2,090.90 lakh, compared to ₹2,049.05 lakh in the corresponding quarter of the previous fiscal year. Earnings per share (basic) were reported at ₹2.26 for the standalone entity and ₹2.23 for the consolidated entity.

What the Numbers Show

While revenue growth remained positive year-on-year, there was a sequential decline in total income from operations, which fell from ₹24,052.19 lakh in Q4FY26 to ₹20,870.93 lakh in Q1FY26. This quarter-over-quarter contraction suggests potential seasonality or specific project cycles affecting the top line. However, the net profit margin remained stable, indicating effective cost management despite the lower revenue base compared to the preceding quarter.